Browse drugs

… the addition of IO to CT in patients with BTC. The addition of IO to CT did not significantly improve survival outcomes over CT a…

… rilvegostomig activity from conventional anti-PD-(L)1 therapy. Rilvegostomig was active in tumors with unique driver mutations, lower CD8+ T…

…s and peripheral blood T-cell responses are ongoing.Conclusions DOC1021 immunotherapy after surgical resection and standard neoadjuvant…

…c-enhanced anti-CTLA-4 monoclonal antibody, in combination with atezolizumab in patients with advanced solid tumors and in MSS CRC. Journal …

…. Patients with untreated advanced GC/GEJ are administered with Q-1802 (IV, Q2W) respectively at 10 mg/kg and 20 mg/kg dose level in c…

…ynx (25%), oral cavity (16.7%), hypopharynx (16.7%).Conclusions TU2218 in combination with Pembrolizumab in patients with HNSCC demons…

…Diego, CA, USA.Wang D, Shinde V, Singh M, Brake R, Kolodziej A. CRB-601, an αvβ8 blocking antibody, prevents activation of TGFβ and exh…

…herapy ( NCT02710253), and the Phase I/Ib Trial of TIraGolumab, AtEzolizumab, and RadScopal Radiation in Patients With Advanced Solid Malign…

…vec (RP1; an HSV-1-based oncolytic immunotherapy) combined with nivolumab demonstrated clinically meaningful, durable antitumor activity …

… relapsed high-risk neuroblastoma includes chemo-immunotherapy: Temozolomide, Irinotecan, and anti-GD2 antibody dinutuximab (TIG). This regi…

…ting safety and preliminary efficacy of intravenous delivery of ATTR-01 in patients with selected epithelial tumors expressing high lev…

…t al. An mTORC1/2 kinase inhibitor enhances the cytotoxicity of gemtuzumab ozogamicin by activation of lysosomal function. Leuk Res. 2018 Nov;74:68–7…